

Financial Statements for the 2nd quarter of fiscal year ending March 31, 2022 (From Apr. 1, 2021 to Sep. 30, 2021)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

November 5, 2021

Highlights in Business Results




(unit: JPY million)

		Apr Sep. 2020	Apr Sep. 2021		Diff	Year-over-	Diff. from	
		Results	Previous Forecast	Results	Diff.	Year	forecast	
Net sales		27,900	29,100	28,275	375	1.3%	(2.8)%	
Operating profit		1,046	950	614	(431)	(41.2)%	(35.3)%	
Ordinary profit		1,127	1,050	683	(444)	(39.4)%	(34.9)%	
Profit attributable to owners of parent		1,060	750	497	(562)	(53.1)%	(33.7)%	
Basic earnings per share		JPY 43.46	JPY 30.71	JPY 20.37				
Exchange Rate	US Dollar	JPY 106.92	JPY 108.00	JPY 109.80		Increased in sales		
(average during period)	Euro	JPY 119.30	JPY 128.00	JPY 129.82		creased in sa ecrease in pro		
(unit: JPY) Singapore Dollar		JPY 76.74	JPY 81.00	JPY 81.80				

Sales	Japan	 Increased sales of capturing new customers for Enteral Nutrition related products under ISO standards Increased sales of COVID-19 related products 		Despite the effect of the sales increase, operating profit decreased due to the impact of higher cost of sales ratio caused by the appreciation of local currencies and increases cost of raw materials at overseas production	
	Ŷ	 Increased sales of AV Fistula Needles 		bases as well as the increase in selling expenses	
	erseas	• Decreased sales of Blood bags and Apheresis kits	Dividend forecast		Interim dividend: JPY 8.5 per share

Summary by segment (geographical area)






*This segment includes Indonesia local subsidiary.

increased sales resulted in profit grows.



Summary by segment (geographical area)





increase in purchase costs caused by soaring marine transportation costs resulted in a reduced


profit.

The influence of the effect of increased sales and reduced expenses, resulted in a profit grows.

Sales by Business Segment Apr. – Sep. 2021 Apr. – Sep. 2020 Others 2.4% Transfusion 16.8% Infusion & Nutrition Apr. – Sep. 41.3% Cardiovascular -2021 8.7% Sales composition 11,670 10,656 Dialysis 30.8% 8,959 8,706 (unit: JPY million) 5,649 +498+25.2% +1,014 +9.5% 4,753 (253) (2.8)% (895) (15.9)% +11 +1.8% 2,473 1,975 660 671 Infusion & Nutrition Dialysis Transfusion Others Cardiovascular

Sales change by Region (Customer's Location)






Selling, General and Admin. Expenses



(unit: IDV million)

(unit: JPY million)




(unit: JPY minit				
	Apr Sep. 2020	Apr Sep. 2021	Diff.	Year -over- Year
Labor Cost	2,869	2,958	89	3.1%
Transport	870	893	22	2.6%
R & D	798	728	(70)	(8.8)%
Depreciation	168	183	15	9.2%
Others	1,731	1,741	10	0.6%
Total	6,439	6,506	67	1.0%

[R&D] Decrease due to completion of large-scale development in the previous fiscal year.

Ordinary profit : Compared with the previous year





Forecast for FYE Mar. 2022



(unit: IPV million)

(unit: JPY million)						
			FYE			
		FYE Mar. 2021 Result	Previous Forecast	New Forecast	Year -over- Year	
Net sales		57,578	58,600	58,000	0.7%	
Operating profit		2,127	2,100	1,200	(43.6)%	
Ordinary profit		2,013	2,300	1,200	(40.4)%	
Profit attributable to owners of parent		1,736	1,700	900	(48.2)%	
Basic earnings per share		JPY 71.13	JPY 69.61	JPY 36.84		
Exchange Rate	US Dollar	JPY 106.06	JPY 108.00	JPY 112.00		
(average during period)	Euro	JPY 121.81	JPY 128.00	JPY 130.00		
(unit: JPY) Singapore Dollar		JPY 77.65	JPY 81.00	JPY 83.00		

Consolidated business forecast for the fiscal year ending March 31, 2022 has been revised, due to the above mentioned business results. The forecast has been calculated based on the assumption that a certain the impact of COVID-19 will still remain in the subsequent consolidated fiscal years.

Topics

Renewed Dialysis Information System 「ERGOTRI」. August 2021

• Strengthened supply system for Low Dead Space Syringes. August 2021

• Formed a business alliance with Fresenius Medical Care. September 2021

 Resolution of the Board of Directors on Selection of Prime Market as New Market Segment on the Tokyo Stock Exchange. October 2021







The Bridge to Good Health Care 11



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.